English

Second quarter results 2010

Report this content

Navamedic ASA Interim Financial report for Q 2 2010.

  • Improved profitability in Vitaflo Scandinavia, following improved Gross Margin and reduced operating costs
  • Registration of the Aspen portfolio progressing according to plan. Product launches expected from 2H 2011
  • Increased cooperation with Aspen with Navamedic taking over sales and marketing responsibility for 8 products from September 1.
  • New experienced CFO commence duty on September 1st 2010, further strengthening Navamedic in its aim to remain a Nordic specialty pharma company.

For further information, please contact:

Olof Milveden, CEO Navamedic ASA

E-mail:olof.milveden@navamedic.com

Office: +46 31 335 11 90
Mobile: +46 733 46 37 36

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Subscribe

Documents & Links